IL137608A0 - Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction - Google Patents

Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction

Info

Publication number
IL137608A0
IL137608A0 IL13760899A IL13760899A IL137608A0 IL 137608 A0 IL137608 A0 IL 137608A0 IL 13760899 A IL13760899 A IL 13760899A IL 13760899 A IL13760899 A IL 13760899A IL 137608 A0 IL137608 A0 IL 137608A0
Authority
IL
Israel
Prior art keywords
benzothiazole
trifluoromethoxy
amino
treating
preventing
Prior art date
Application number
IL13760899A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL137608A0 publication Critical patent/IL137608A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13760899A 1998-02-06 1999-02-03 Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction IL137608A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (1)

Publication Number Publication Date
IL137608A0 true IL137608A0 (en) 2001-07-24

Family

ID=9522673

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13760899A IL137608A0 (en) 1998-02-06 1999-02-03 Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction
IL137608A IL137608A (en) 1998-02-06 2000-07-31 Use of 2-amino-6-trifluoromethoxy-benzothiazole in the preparation of drugs for the prevention or treatment of dysfunction of the serum

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137608A IL137608A (en) 1998-02-06 2000-07-31 Use of 2-amino-6-trifluoromethoxy-benzothiazole in the preparation of drugs for the prevention or treatment of dysfunction of the serum

Country Status (18)

Country Link
US (1) US6245791B1 (es)
EP (1) EP1052989B1 (es)
JP (1) JP5127092B2 (es)
KR (1) KR100574378B1 (es)
AT (1) ATE245982T1 (es)
AU (1) AU761978B2 (es)
CA (1) CA2319686C (es)
DE (1) DE69909970T2 (es)
DK (1) DK1052989T3 (es)
EA (1) EA002676B1 (es)
ES (1) ES2199541T3 (es)
FR (1) FR2774592B1 (es)
IL (2) IL137608A0 (es)
NO (1) NO327819B1 (es)
NZ (1) NZ506124A (es)
PT (1) PT1052989E (es)
WO (1) WO1999039710A1 (es)
ZA (1) ZA99740B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
AU2019277080A1 (en) * 2018-05-27 2021-01-07 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
DE69909970D1 (de) 2003-09-04
CA2319686A1 (fr) 1999-08-12
EP1052989A1 (fr) 2000-11-22
NO20003785L (no) 2000-07-24
KR20010040671A (ko) 2001-05-15
JP5127092B2 (ja) 2013-01-23
WO1999039710A1 (fr) 1999-08-12
CA2319686C (fr) 2009-06-23
NZ506124A (en) 2003-07-25
FR2774592A1 (fr) 1999-08-13
JP2002502819A (ja) 2002-01-29
AU761978B2 (en) 2003-06-12
EA002676B1 (ru) 2002-08-29
NO20003785D0 (no) 2000-07-24
DE69909970T2 (de) 2004-05-27
FR2774592B1 (fr) 2000-03-17
DK1052989T3 (da) 2003-11-17
ES2199541T3 (es) 2004-02-16
KR100574378B1 (ko) 2006-04-26
ATE245982T1 (de) 2003-08-15
US6245791B1 (en) 2001-06-12
EA200000816A1 (ru) 2001-02-26
EP1052989B1 (fr) 2003-07-30
PT1052989E (pt) 2003-12-31
NO327819B1 (no) 2009-09-28
IL137608A (en) 2006-09-05
ZA99740B (en) 1999-08-02
AU2171199A (en) 1999-08-23

Similar Documents

Publication Publication Date Title
ZA200006042B (en) Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections.
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
GB0225475D0 (en) Therapeutic agents
AP2004003123A0 (en) Thiazole and oxazole derivatives that modulate PPAR activity
PT1071422E (pt) Associações de riluzole e levodopa para o tratamento da doença de parkinson
ZA200202461B (en) Compounds for the treatment of ischemia.
GR3022356T3 (en) Use of lamotrigine for treating aids-related neural disorders
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
IL137608A0 (en) Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
HK1050480A1 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.
GB9917158D0 (en) New use
ZA200006374B (en) Compound for the treatment of female sexual dysfunction.
WO2000007582A3 (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
PA8505301A1 (es) Metodo para tratar el mal de parkinson a traves de la administracion de ( - ) - 5 ceto-2-n- propilamino - tetrahidrotetralina
MX9603819A (es) Tratamiento de tinnitus empleando agentes neuroprotectores.
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed